Interferon-gamma therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals

HIV Clin Trials. 2004 Mar-Apr;5(2):80-5. doi: 10.1310/T4R0-WBPL-Q2Q6-TU49.

Abstract

Defective immunological function of cells of the macrophage lineage contributes to the pathogenesis of HIV-1 infection. Because monocyte/macrophage function is enhanced by cytokines such as interferon-gamma (IFN-gamma), the use of this immunomodulator is of potential clinical interest as adjunctive immunotherapy in immunosuppressed individuals. In this study, we show that adjunctive IFN-gamma treatment in an HIV-infected individual with Mycobacterium avium complex (MAC) infection increased phagocytosis of MAC by blood monocytes when compared to cells from an HIV-infected patient who was receiving standard chemotherapy alone. Enhanced phagocytic efficiency resulting from IFN-gamma therapy was associated with increased surface expression of MHC II (HLA-DR), a phagocytic receptor (CD16), and the activation marker (CD69), although the levels of activation markers were dissimilar at baseline in the two participants. These results imply that IFN-gamma may be useful in restoring antimycobacterial function in immunosuppressed patients.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Flow Cytometry
  • HIV-1 / immunology*
  • Humans
  • Immunocompromised Host
  • Interferon-gamma / administration & dosage*
  • Macrophage Activation / drug effects
  • Mycobacterium avium Complex / immunology*
  • Mycobacterium avium-intracellulare Infection / drug therapy*
  • Mycobacterium avium-intracellulare Infection / immunology
  • Opportunistic Infections / drug therapy*
  • Opportunistic Infections / immunology
  • Phagocytosis / drug effects*
  • Pilot Projects

Substances

  • Antiviral Agents
  • Interferon-gamma